For research use only. Not for therapeutic Use.
MIF098 is a macrophage migration inhibitory factor (MIF) antagonist. MIF098 inhibits proliferation, migration and fibrosis of pulmonary smooth muscle cells. MIF098 can be used for immunoinflammation-related disease research[1].
MIF098 (0-10 μM, 48 h) inhibits mPASMC cell proliferation and migration in a concentration-dependent manner, by blocking the migration inhibitory factor (MIF) pathway[1].
MIF098 reduces collagen synthesis and pulmonary artery fibrosis by inhibiting the TGFβ1/Smad2/3 pathway[1].
MIF098 (intraperitoneal injection, 40 mg/kg, once a day, 4 weeks) attenuates the process of hypoxia-induced pulmonary arterial hypertension in C57BL/6J mice[1].
| Catalog Number | I043367 |
| CAS Number | 1208448-95-6 |
| Synonyms | 3-[(3-hydroxyphenyl)methyl]-5-methyl-1,3-benzoxazol-2-one |
| Molecular Formula | C15H13NO3 |
| Purity | ≥95% |
| InChI | InChI=1S/C15H13NO3/c1-10-5-6-14-13(7-10)16(15(18)19-14)9-11-3-2-4-12(17)8-11/h2-8,17H,9H2,1H3 |
| InChIKey | JJXKGUBHEQGADG-UHFFFAOYSA-N |
| SMILES | CC1=CC2=C(C=C1)OC(=O)N2CC3=CC(=CC=C3)O |
| Reference | [1]. HuijingHuang, et al. The small molecule macrophage migration inhibitory factor antagonist MIF098, inhibits pulmonary hypertension associated with murine SLE. Int Immunopharmacol. 2019 Nov;76:105874. |
